HotHouse Therapeutics

HotHouse Therapeutics is a drug discovery platform company that engineers plants as sustainable biofactories for pharmaceutical compound production.

Using AI to design and optimise biosynthetic pathways, it produces both natural and new-to-nature molecules via transient and stable plant expression systems capable of GMP output.

Initial commercial focus is next-generation saponin-based vaccine adjuvants, including sustainable alternatives to QS-21.

The company's science originates from natural product research at the John Innes Centre.